Table 1.
Baseline characteristics of study participants.
| |
The groups by vaccine used as the first and second dose |
||||||
|---|---|---|---|---|---|---|---|
| CoronaVac -ChAdOx1 | CoronaVac -BNT162b2 | ChAdOx1 - CoronaVac | ChAdOx1- BNT162b2 | BNT162b2 -CoronaVac | BNT162b2 -ChAdOx1 | BNT162b2 -BNT162b2 | |
| Numbers of enrolled participants | n = 30 | n = 30 | n = 30 | n = 30 | n = 30 | n = 30 | n = 30 |
| Age (years), median, IQR | 39 (33, 46) |
30.5 (24, 38) |
40.5 (36, 48) |
39 (29, 43) |
34.5 (25, 47) |
32.5 (26, 41) |
36.5 (32, 43) |
| Female, n (%) | 15 (50) | 18 (60) | 14 (46.67) | 19 (63.33) | 13 (43.3) | 16 (53.3) | 13 (43.3) |
| BMI, median (IQR) | 25.25 (22.70, 28.10) |
23.40 (21.00, 26.50) |
23.5 (21.30, 26.00) |
20.95 (19.60, 24.50) |
24.15 (20.10, 27.70) |
24.35 (20.80, 28.70) |
24.30 (21.40, 26.10) |
| Hypertension, n (%) | 1 (3.33) | 0 | 4 (13.33) | 1 (3.33) | 0 | 2 (6.67) | 0 |
| Dyslipidemia, n (%) | 0 | 0 | 2 (6.67) | 0 | 0 | 2 (6.67) | 0 |
| Diabetes, n (%) | 0 | 0 | 1 (3.33) | 0 | 0 | 0 | 0 |